ArticleCureus2025
Assessment of Gastroesophageal Reflux Disease in Patients Exhibiting Otolaryngology Symptoms at a Tertiary Care Hospital.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background Gastroesophageal reflux disease (GERD) is characterized by repeated episodes of heartburn sensation or regurgitation; it can also present as extraesophageal symptoms, which include dysphagia and hoarseness alongside throat clearing. Patients frequently present with atypical GERD symptoms, which trigger admission to otolaryngology (ENT) practices; however, this often results in patients missing the opportunity for proper diagnosis and treatment by gastroenterologists. Objectives This study aims to analyze the frequency of ENT complaints among GERD patients referred to gastroenterology from ENT and to determine their response to proton pump inhibitor (PPI) therapy based on structured clinic follow-up regarding symptomatic improvement following initiation of the regimen. Methods This retrospective record review study was conducted at a tertiary hospital in Saudi Arabia, between January 1, 2018, and December 31, 2023. A total of 263 adult patients diagnosed with GERD and referred for ENT-related symptoms were included using consecutive sampling. Inclusion criteria were age ≥17 years, confirmed GERD based on either clinical or endoscopic findings via the Los Angeles classification (LA) grading system, and documented ENT complaints (e.g., sore throat, dysphagia, hoarseness, halitosis). Exclusion criteria were incomplete records, chronic pulmonary disease, or a history of neck/glottic surgery, radiotherapy, or malignancy. Data were collected from hospital records and analyzed using IBM SPSS Statistics for Windows, version 26 (IBM Corp., Armonk, New York, United States). The chi-square test was used to assess associations, with p<0.05 considered significant. Results The participants had a mean age of 50.7 years ± 20.2 years, with 168 female patients (63.9%) in the sample. The majority of patients (78.3%) exhibited GERD LA grade A, whereas dysphagia in 83 patients (31.6%) and sore throat in 74 patients (28.1%) were the most frequent ENT symptoms among patients. GERD LA grade C was significantly correlated with halitosis development (P<0.001). The treatment benefit reached 230 patients (87.5%), but halitosis development (p<0.001), snoring (p=0.01), and shortness of breath (p=0.036) were associated with unfavorable treatment responses. Conclusions Patients with ENT symptoms may have GERD even in the absence of typical reflux symptoms. Symptoms of halitosis and snoring indicate advanced or treatment-resistant GERD. Accurate diagnosis and effective management depend on tight collaboration between multiple medical disciplines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.